

AMENDMENTS TO THE CLAIMS:

This listing of the claims replaces any and all prior versions and listings of claims in the application:

1. Cancelled
2. Cancelled
3. Cancelled
4. Cancelled
5. Cancelled
6. Cancelled
7. Cancelled
8. Cancelled
9. (Currently Amended) A method of inhibiting the proliferation of cancer cells in a subject comprising administering, to the subject, an effective amount of ~~the therapeutic composition of claim 1~~ an isolated peptide having a sequence selected from:
Cys Val His Ala Tyr Arg Ser (SEQ ID NO:1);
Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2);
Cys Val His Ala Phe Arg Ser (SEQ ID NO:3);
Cys Val His Ala Phe Arg Ala (SEQ ID NO:4);
Cys Val His Ser Tyr Arg Ser (SEQ ID NO:5);
Cys Val His Ser Tyr Arg Ala (SEQ ID NO:6);
Cys Val His Ser Phe Arg Ser (SEQ ID NO:7);
Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);
Cys Val His Thr Tyr Arg Ser (SEQ ID NO:9);
Cys Val His Thr Tyr Arg Ala (SEQ ID NO:10);
Cys Val His Thr Phe Arg Ser (SEQ ID NO:11);
Cys Val His Thr Phe Arg Ala (SEQ ID NO:12); and a combination thereof.
10. (Original) The method of claim 9, where the cancer cells are breast cancer cells.
11. (Original) The method of claim 9, where the cancer cells are lung cancer cells.

12. (Original) The method of claim 9, where the cancer cells are colon cells.
13. (Original) The method of claim 9, where the cancer cells are melanoma cells.
14. (Original) The method of claim 9, where the cancer cells are leukemia cells.
15. (Currently Amended) A method of inhibiting ~~the effects of the proliferation of viral~~ infection in a subject comprising administering, to the subject, an effective amount of ~~the~~ therapeutic composition of claim 1 an isolated peptide having a sequence selected from:
Cys Val His Ala Tyr Arg Ser (SEQ ID NO:1);
Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2);
Cys Val His Ala Phe Arg Ser (SEQ ID NO:3);
Cys Val His Ala Phe Arg Ala (SEQ ID NO:4);
Cys Val His Ser Tyr Arg Ser (SEQ ID NO:5);
Cys Val His Ser Tyr Arg Ala (SEQ ID NO:6);
Cys Val His Ser Phe Arg Ser (SEQ ID NO:7);
Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);
Cys Val His Thr Tyr Arg Ser (SEQ ID NO:9);
Cys Val His Thr Tyr Arg Ala (SEQ ID NO:10);
Cys Val His Thr Phe Arg Ser (SEQ ID NO:11);
Cys Val His Thr Phe Arg Ala (SEQ ID NO:12); and a combination thereof.
16. (Original) The method of claim 15, where the virus is human immunodeficiency virus type 1.
17. (Original) The method of claim 15, where the virus is a Bunyavirus.
18. (Original) The method of claim 15, where the virus is a Togavirus.
19. (Original) The method of claim 15, where the virus is a Reovirus.
20. (Original) The method of claim 15, where the virus is a Herpesvirus.
21. (Original) The method of claim 15, where the virus is a Poxvirus.

22. (Currently Amended) An ~~antiproliferative~~ isolated peptide having a sequence selected from: ~~the group consisting of~~

Cys Val His Ala Tyr Arg Ser (SEQ ID NO:1);
Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2);
Cys Val His Ala Phe Arg Ser (SEQ ID NO:3);
Cys Val His Ala Phe Arg Ala (SEQ ID NO:4);
Cys Val His Ser Tyr Arg Ser (SEQ ID NO:5);
Cys Val His Ser Tyr Arg Ala (SEQ ID NO:6);
Cys Val His Ser Phe Arg Ser (SEQ ID NO:7);
Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);
Cys Val His Thr Tyr Arg Ser (SEQ ID NO:9);
Cys Val His Thr Tyr Arg Ala (SEQ ID NO:10);
Cys Val His Thr Phe Arg Ser (SEQ ID NO:11); and
Cys Val His Thr Phe Arg Ala (SEQ ID NO:12).

23. Canceled

24. Canceled

25. (New) A composition comprising an excipient and an isolated peptide having a sequence selected from:

Cys Val His Ala Tyr Arg Ser (SEQ ID NO:1);
Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2);
Cys Val His Ala Phe Arg Ser (SEQ ID NO:3);
Cys Val His Ala Phe Arg Ala (SEQ ID NO:4);
Cys Val His Ser Tyr Arg Ser (SEQ ID NO:5);
Cys Val His Ser Tyr Arg Ala (SEQ ID NO:6);
Cys Val His Ser Phe Arg Ser (SEQ ID NO:7);
Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);
Cys Val His Thr Tyr Arg Ser (SEQ ID NO:9);
Cys Val His Thr Tyr Arg Ala (SEQ ID NO:10);

Cys Val His Thr Phe Arg Ser(SEQ ID NO:11);

Cys Val His Thr Phe Arg Ala (SEQ ID NO:12) and combination thereof.